Drug Profile
Cilomilast
Alternative Names: AL-38583; Ariflo; SB 207499; SKB 207499Latest Information Update: 14 Mar 2012
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer Alcon; GlaxoSmithKline
- Class Antibronchitics; Carboxylic acids; Nitriles; Small molecules
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Chronic obstructive pulmonary disease; Dry eyes; Ocular inflammation
Most Recent Events
- 14 Mar 2012 Discontinued - Phase-II for Dry eyes in USA (Ophthalmic)
- 14 Mar 2012 Discontinued - Phase-II for Ocular inflammation in USA (Ophthalmic)
- 14 Mar 2012 Discontinued - Phase-III for Chronic obstructive pulmonary disease in USA (PO)